Catalent, Inc. (NYSE:CTLT) Stake Lessened by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System decreased its position in shares of Catalent, Inc. (NYSE:CTLT) by 2.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,200 shares of the company’s stock after selling 300 shares during the period. Louisiana State Employees Retirement System’s holdings in Catalent were worth $574,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Lindbrook Capital LLC increased its position in shares of Catalent by 79.4% during the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after purchasing an additional 208 shares during the period. GAMMA Investing LLC bought a new position in Catalent during the fourth quarter valued at about $33,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Catalent during the second quarter worth about $42,000. Mather Group LLC. bought a new stake in Catalent in the first quarter worth about $52,000. Finally, Federated Hermes Inc. acquired a new stake in Catalent in the 4th quarter valued at about $46,000.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Barclays boosted their target price on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a report on Friday, June 28th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a report on Thursday, July 11th. Finally, StockNews.com began coverage on Catalent in a research report on Sunday, August 25th. They set a “sell” rating for the company. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Catalent has an average rating of “Hold” and a consensus price target of $57.06.

Insider Buying and Selling

In other news, insider Ricky Hopson sold 662 shares of the stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $59.56, for a total value of $39,428.72. Following the completion of the sale, the insider now directly owns 29,974 shares of the company’s stock, valued at $1,785,251.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Ricky Hopson sold 662 shares of the business’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.56, for a total transaction of $39,428.72. Following the transaction, the insider now directly owns 29,974 shares in the company, valued at approximately $1,785,251.44. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Matti Masanovich sold 2,993 shares of the stock in a transaction on Monday, July 8th. The stock was sold at an average price of $56.74, for a total value of $169,822.82. Following the sale, the chief financial officer now owns 33,871 shares of the company’s stock, valued at $1,921,840.54. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,810 shares of company stock valued at $858,941. Corporate insiders own 0.31% of the company’s stock.

Catalent Stock Up 0.0 %

Shares of NYSE:CTLT opened at $60.96 on Friday. Catalent, Inc. has a 52 week low of $31.80 and a 52 week high of $61.20. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51. The company has a market cap of $11.03 billion, a PE ratio of -9.99, a price-to-earnings-growth ratio of 2.47 and a beta of 1.16. The firm has a 50 day simple moving average of $58.45 and a 200 day simple moving average of $56.96.

Catalent (NYSE:CTLT) last released its earnings results on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.13. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. The company had revenue of $1.30 billion during the quarter, compared to analyst estimates of $1.23 billion. As a group, research analysts expect that Catalent, Inc. will post -0.17 earnings per share for the current year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.